Conclusions: This study identified a population of patients with multiple potentially HPV-related tumors and demonstrates differ- ent outcomes based on multiple factors, including the site of first diagnosis and duration between diagnoses. Interval between diagnoses was also found to depend upon the site of the initial tumor. In patients presenting with a potentially HPV-related ma- lignancy,anopportunityforsecondarycancerpreventionmayexistthroughbehaviormodificationandalteredscreening, butfuture work is needed to establish true HPV-positivity in this cohort and to understand a potential role for vaccine and chemoprevention strategies. Results: All patients in p-CAIR completed radiotherapy as prescribed, with no need for unplanned interruptions. By contrast, only 59% of the patients in p-CRT received 3 courses of chemotherapy, while cisplatin was discontinued after 2 courses in 37%, and after thefirst coursein4%. Two patientsinp-CRT hadradiation treatmentinterruptions of7 days ormore.Severeadverseeventsin p-CRT included one patient that died due to sepsis (2.4%), one patient with pulmonary embolism (2.4%) and 5 cases of neurotox- icity (12.1%). In addition, 32% of the patients in p-CRT had grade 3 neutropenia, compared to 0% in p-CAIR (p\0.001). The average hemoglobin concentration at the end of radiotherapy was significantly lower in p-CRT compared to p-CAIR (13.5 g/dl vs. 12.0 g/dl, p = 0.02. The platelets count at the end of radiotherapy was lower in p-CRT vs. p-CAIR, but the difference was not sig- nificant (250*10 5 vs. 210*10 5 , p = 0.12). The average maximum total severity score for mucosal reactions was significantly higher in patients treated with p-CAIR compared to p-CRT (15.3 vs. 13.0, p = 0.03). The average duration of severe mucosal reactions (score $10) did not, however, differ significantly in the respective arms (2.9 weeks p-CAIR vs. 2.6 weeks p-CRT). Conclusions: The early tolerance of p-RCT was considerably affected by hematological and neurological reactions that necessi- tated discontinuation of chemotherapy in 41% of the patients. The maximal intensity of acute mucosal reactions was higher in p- CAIR compared to p-RCT, but the duration of severe reactions did not differ significantly between the arms.